5,4'-Dihydroxy-7,3',5'-trimethoxyflavone | 107316-94-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 5,4'-Dihydroxy-7,3',5'-trimethoxyflavone
• 英文别名: 5-hydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-7-methoxychromen-4-one
• CAS: 107316-94-9
• 化学式: C₁₈H₁₆O₇
• 分子量: 344.3
• InChiKey: VIKKUMIXGIDYKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  94.4
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF
  申请人：Manuka Health New Zealand Limited

  公开号：EP2981254A1

  公开（公告）日：2016-02-10
• THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF FOR THE TREATMENT OF GASTRIC CANCER
  申请人：Manuka Health New Zealand Limited

  公开号：EP2981254B1

  公开（公告）日：2018-10-10
• Therapeutic Compositions and Uses Thereof
  申请人：MANUKA HEALTH NEW ZEALAND LIMITED

  公开号：US20160030364A1

  公开（公告）日：2016-02-04

  This invention provides pharmaceutical compositions comprising compounds including 5-phenylpenta-2,4-dienoic acid, 3-methyl-3-butenyl caffeic acid, 1,1-dimethylallyl caffeic acid, pinobanksin-3-acetate, tectochrysin, pinostrobin chalcone, benzyl ferulate and benzyl isoferulate. Methods of using such compositions, in particular in the treatment or prevention of gastrointestinal cancers, and the resensitisation of gastrointestinal cancers to therapy are also provided.
• [EN] THERAPEUTIC COMPOSITIONS COMPRISING EXTRACTS OF PROPOLIS AND USES THEREOF<br/>[FR] COMPOSITIONS THÉRAPEUTIQUES COMPRENANT DES EXTRAITS DE PROPOLIS ET LEURS UTILISATIONS
  申请人：MANUKA HEALTH NEW ZEALAND LTD

  公开号：WO2014163512A1

  公开（公告）日：2014-10-09

  This invention provides pharmaceutical compositions comprising compounds including 5-phenylpenta-2, 4-dienoic acid, 3-methyl-3-butenyl caffeic acid, 1,1-dimethylallyl caffeic acid, pinobanksin-3-acetate, tectochrysin, pinostrobin chalcone, benzyl ferulate and benzyl isoferulate. Methods of using such compositions, in particular in the treatment or prevention of gastrointestinal cancers, and the resensitisation of gastrointestinal cancers to therapy are also provided.